Dr. Callander Discusses Combinations in Multiple Myeloma

Natalie S. Callander, MD
Published: Wednesday, Oct 11, 2017



Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses combinations in multiple myeloma.

Both the POLLUX and CASTOR trials showed high response rates with the use of triplets that involved daratumumab (Darzalex), says Callander.

Callander adds that combinations with elotuzumab (Empliciti), as well as ixazomib (Ninlaro), have shown excellent results as well.
 


Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses combinations in multiple myeloma.

Both the POLLUX and CASTOR trials showed high response rates with the use of triplets that involved daratumumab (Darzalex), says Callander.

Callander adds that combinations with elotuzumab (Empliciti), as well as ixazomib (Ninlaro), have shown excellent results as well.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x